These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 20392299

  • 1. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Bröcheler A, Boy C, Cumming P, Hiemke C, Rösch F, Schäfer WM, Gründer G.
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [Abstract] [Full Text] [Related]

  • 2. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P.
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [Abstract] [Full Text] [Related]

  • 3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [Abstract] [Full Text] [Related]

  • 4. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [Abstract] [Full Text] [Related]

  • 5. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
    Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY.
    Neuropsychopharmacology; 2006 Sep; 31(9):1991-2001. PubMed ID: 16738543
    [Abstract] [Full Text] [Related]

  • 6. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
    Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS.
    Br J Psychiatry; 2000 Nov; 177():408-15. PubMed ID: 11059993
    [Abstract] [Full Text] [Related]

  • 7. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [Abstract] [Full Text] [Related]

  • 8. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G, Baumann P, Kiessling B, Reinert M, Wiedemann G, Kehr J, Mathé AA, Piel M, Roesch F, Weisser H, Schneider P, Hertel A.
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [Abstract] [Full Text] [Related]

  • 9. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
    Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY.
    Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
    [Abstract] [Full Text] [Related]

  • 10. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [Abstract] [Full Text] [Related]

  • 11. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
    Tauscher J, Küfferle B, Asenbaum S, Brücke T, Kasper S.
    Psychopharmacology (Berl); 1997 Sep; 133(1):102-5. PubMed ID: 9335088
    [Abstract] [Full Text] [Related]

  • 12. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H, Kuikka JT, Viinamäki H, Husso M, Tiihonen J.
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [Abstract] [Full Text] [Related]

  • 13. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy.
    Landvogt C, Buchholz HG, Bernedo V, Schreckenberger M, Werhahn KJ.
    Epilepsia; 2010 Sep; 51(9):1699-706. PubMed ID: 20384765
    [Abstract] [Full Text] [Related]

  • 14. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [Abstract] [Full Text] [Related]

  • 15. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.
    Riccardi P, Baldwin R, Salomon R, Anderson S, Ansari MS, Li R, Dawant B, Bauernfeind A, Schmidt D, Kessler R.
    Biol Psychiatry; 2008 Jan 15; 63(2):241-4. PubMed ID: 17586476
    [Abstract] [Full Text] [Related]

  • 16. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.
    Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.
    Biol Psychiatry; 2010 Oct 01; 68(7):634-41. PubMed ID: 20673873
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May 01; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 20. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R.
    Psychopharmacology (Berl); 1998 Jan 01; 135(2):119-26. PubMed ID: 9497016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.